Quantcast

Latest Dextromethorphan Stories

2014-08-26 08:31:43

--Study to Utilize Sequential Parallel Comparison Design to Minimize Placebo Response, Same Design Utilized in AVP-923 Phase II Study in Agitation in Alzheimer's Disease-- ALISO VIEJO, Calif., Aug. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient into a phase II study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). AVP-786 is a novel...

2014-08-05 16:27:40

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights -- Total company net revenues of $28.6 million. -- Net NUEDEXTA® sales of $26.5 million. -- Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with...

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...

2014-06-30 20:22:37

ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela...

2014-05-30 08:25:39

ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul -- Burden of...

2014-05-27 08:29:52

ALISO VIEJO, Calif., May 27, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO "Final completion of enrollment in this study is an important milestone for...

2014-05-06 16:32:33

ALISO VIEJO, Calif., May 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Quarterly Financial Highlights -- Total company net revenues of $26.9 million -- Net NUEDEXTA® sales of $24.4 million -- Cash, cash equivalents, and restricted investments of $56.5 million as of March 31, 2014. "We are extremely pleased...

2014-04-30 16:30:05

ALISO VIEJO, Calif., April 30, 2014, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs') for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the...

2014-04-28 08:27:50

New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66(th) American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology,...

2014-03-20 08:30:39

Data shows that dextromethorphan exerts antidepressant-like actions mediated at least in part through sigma-1 receptors ALISO VIEJO, Calif., March 20, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related